Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,633,071
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
34,758,681
-
Shares change
-
-1,857,606
-
Total reported value, excl. options
-
$319,233,355
-
Value change
-
-$17,282,962
-
Put/Call ratio
-
63%
-
Number of buys
-
62
-
Number of sells
-
-51
-
Price
-
$9.18
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2021
136 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2021.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,758,681 shares
of 49,633,071 outstanding shares and own 70.03% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3,769,795 shares), VANGUARD GROUP INC (3,586,043 shares), BlackRock Inc. (3,065,764 shares), FRED ALGER MANAGEMENT, LLC (2,985,976 shares), Camber Capital Management LP (2,725,000 shares), RENAISSANCE TECHNOLOGIES LLC (1,598,335 shares), STATE STREET CORP (1,529,520 shares), Palo Alto Investors LP (1,392,997 shares), GREAT POINT PARTNERS LLC (1,300,000 shares), and ACADIAN ASSET MANAGEMENT LLC (1,227,479 shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.